The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | Nodular lymphocyte-predominant Hodgkin lymphoma
Dennis Eichenauer, MD, University Hospital of Cologne, Cologne, Germany, discusses nodular lymphocyte-predominant Hodgkin lymphoma (HL), a rare subtype of HL that accounts for around 5% of all cases, and presents with distinct pathological and clinical characteristics. Dr Eichenauer touches on differences in treatment and progression of nodular lymphocyte-predominant HL in comparison to classical HL and provides an overview of the treatment approach for this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
